Scholarlink

<p>There is a lack of comprehensive research investigating the relationship between proton pump inhibitors (PPIs) and osimertinib combination therapy concerning cardiotoxicity. We conducted a retrospective analysis of adverse event reports from the US Food and Drug Administration Adverse Event Reporting System (FAERS). In this analysis, we used patients with non-small cell lung cancer (NSCLC) who did not receive osimertinib or PPIs as a control group to assess the association between cardiotoxicity occurrence in patients receiving osimertinib with PPIs and those without PPIs. We employed disproportionality analysis along with both additive and multiplicative models. The reporting odds ratios (ROR) for cardiac events, including torsade de pointes/QT prolongation, cardiomyopathy, cardiac arrhythmias, cardiac failure, ischaemic heart disease, and embolic and thrombotic events, were significantly higher in patients using PPIs with osimertinib (14.11, 9.04–22.04; 4.67, 2.67–8.16; 4.43, 3.17–6.20; 3.67, 2.53–5.34; 2.24, 1.31–3.84; 1.92, 1.43–2.56, respectively) compared to osimertinib alone (4.87, 3.91–6.07; 2.50, 2.02–3.09; 1.59, 1.37–1.84; 2.00, 1.74–2.29; 0.65, 0.50–0.84; 1.01, 0.91–1.11). Our investigation unveiled an elevated risk of cardiotoxicity in NSCLC patients when osimertinib was combined with PPIs, compared to osimertinib monotherapy. Therefore, vigilant monitoring for cardiotoxicity is paramount in NSCLC patients undergoing these combined treatments.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of Proton Pump Inhibitors on Osimertinib-Induced Cardiotoxicity in NSCLC Patients

  • 期刊论文

  • 发表日期：

    2025年5月9日

查看全文
  • Haitao Wang,
  • Sinan Ma,
  • Weijia Huang,
  • Keyu Chen,
  • Jiao Xie,
  • Na Wang,
  • Youjia Li,
  • Qianting Yang,
  • Xin Yang,
  • Yan Wang

摘要

There is a lack of comprehensive research investigating the relationship between proton pump inhibitors (PPIs) and osimertinib combination therapy concerning cardiotoxicity. We conducted a retrospective analysis of adverse event reports from the US Food and Drug Administration Adverse Event Reporting System (FAERS). In this analysis, we used patients with non-small cell lung cancer (NSCLC) who did not receive osimertinib or PPIs as a control group to assess the association between cardiotoxicity occurrence in patients receiving osimertinib with PPIs and those without PPIs. We employed disproportionality analysis along with both additive and multiplicative models. The reporting odds ratios (ROR) for cardiac events, including torsade de pointes/QT prolongation, cardiomyopathy, cardiac arrhythmias, cardiac failure, ischaemic heart disease, and embolic and thrombotic events, were significantly higher in patients using PPIs with osimertinib (14.11, 9.04–22.04; 4.67, 2.67–8.16; 4.43, 3.17–6.20; 3.67, 2.53–5.34; 2.24, 1.31–3.84; 1.92, 1.43–2.56, respectively) compared to osimertinib alone (4.87, 3.91–6.07; 2.50, 2.02–3.09; 1.59, 1.37–1.84; 2.00, 1.74–2.29; 0.65, 0.50–0.84; 1.01, 0.91–1.11). Our investigation unveiled an elevated risk of cardiotoxicity in NSCLC patients when osimertinib was combined with PPIs, compared to osimertinib monotherapy. Therefore, vigilant monitoring for cardiotoxicity is paramount in NSCLC patients undergoing these combined treatments.

Graphical Abstract